Advair “approvable” again
Executive Summary
GlaxoSmithKline Advair Diskus for chronic obstructive pulmonary disease receives its second "approvable" letter Dec. 12. In March, FDA requested more efficacy data for the sNDA (1"The Pink Sheet" April 1, p. 27)...